Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049986 | 0.85 | EGFR (0.55) | CYP3A4EGFRHDAC6HDAC1HDAC5 | |
| SCHEMBL29831918 | 0.83 | EGFR (0.59) | CYP3A4EGFRNPC1RAB9AMAOB | |
| SCHEMBL24124319 | 0.82 | F2 (0.58) | CYP3A4EGFRRAB9AMEN1KMT2A | |
| SCHEMBL24124325 | 0.81 | MEN1 (0.59) | CYP3A4EGFRRAB9AMEN1KMT2A | |
| SCHEMBL25920276 | 0.80 | PPARA (0.48) | CYP3A4EGFRRAB9AMAOBMEN1 | |
| SCHEMBL24124645 | 0.79 | RAB9A (0.61) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL1412056 | 0.78 | ALOX5 (0.67) | CYP3A4ALOX5NPC1RAB9AMAOB | |
| SCHEMBL30125417 | 0.78 | CYP3A4 (1.00) | CYP3A4ALOX5NPC1RAB9AHDAC6 | |
| SCHEMBL841728 | 0.78 | CYP3A4 (1.00) | CYP3A4ALOX5NPC1RAB9AHDAC6 | |
| SCHEMBL24124769 | 0.78 | F2 (0.53) | EGFRRAB9AMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102603718-B | Synthesis method of cediranib | CHEMPROSPECT PHARMTECH CO LTD | 2014-01-29 | — | — | CN | claimed |
| CN-104744446-B | Heteroaryl compound and its application in drug | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-104098551-B | Substituted quinazoline analog derivative as Ou Ruola kinase inhibitor | 广东东阳光药业有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-102503933-B | Chemical method of producing quinazoline derivative | ASTRAZENECA AB | 2014-06-25 | — | — | CN | disclosed |
| CN-102532107-B | 4-substituted aniline-7-substituted alcoxylhomopiperazine-quinazoline derivatives, and preparation method and application thereof | TIANJIN INST PHARM RESEARCH | 2014-03-12 | — | — | CN | disclosed |
| CN-102603718-B | Synthesis method of cediranib | CHEMPROSPECT PHARMTECH CO LTD | 2014-01-29 | — | — | CN | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| CN-100345844-C | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| CN-1434821-A | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | CYP3A4 1087/4885ALOX5 4275/4885EGFR 4/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | CYP3A4 1781/4885ALOX5 4139/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.